In 2025, Cellectis S.A. achieved a 75.8% year-over-year revenue growth to $72.95 million, primarily fueled by milestone payments, royalties, and cost reimbursements from strategic collaborations including AstraZeneca. Despite this revenue expansion, the company recorded a net loss of $67.6 million due to sustained high research and development expenses exceeding $93 million annually and selling, general and administrative costs near $19.8 million. The negative return on equity of approximately -89.1% reflects the company's focus on advancing its gene-edited allogeneic CAR T-cell therapy pipeline through clinical trials such as BALLI-01 and NATHALI-01. Supported by $61.5 million in cash and $144.8 million in fixed-term deposits at year-end 2025, Cellectis maintains adequate liquidity for operations into mid-2027 but remains dependent on continued funding and regulatory progress amid patent litigation risks.